Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Three APRIL/BAFF-inhibiting drugs — sibeprenlimab, atacicept, and telitacicept — demonstrated remarkable 2-year results in IgA nephropathy, dramatically slowing kidney function decline compared to placebo. Phase 3 trial data presented at Kidney Week 2026 showed risk reductions in composite kidney disease progression far exceeding those of existing therapies. Experts are calling the findings potentially "game-changing" for a disease that once carried a 50% risk of progressing to end-stage kidney failure.
IgA nephropathy — the most common primary glomerular disease, typically striking in young adulthood — has long been difficult to treat. Standard therapies like SGLT2 inhibitors and RAAS inhibitors slow progression but often can't stop patients from eventually reaching kidney failure. Now, three new drugs targeting the APRIL/BAFF pathway are rewriting the playbook, with 2-year phase 3 data presented at Kidney Week 2026 showing unprecedented preservation of kidney function.
All three drugs work by modulating B cells, which sit at the core of IgA nephropathy's disease mechanism. Sibeprenlimab and atacicept have already received FDA accelerated approvals based on earlier interim data, and the latest 2-year results — simultaneously published in the New England Journal of Medicine — only strengthen the case for this drug class.
By the Numbers:
Why it matters: These results far exceed the 16%–55% risk reductions seen in landmark CKD trials and the 25%–30% proteinuria reductions with standard care. Experts note that if effects hold in patients with more advanced disease (eGFR below 30–40), clinicians may finally have tools capable of truly modifying — not just slowing — the course of IgA nephropathy, a condition that affects patients globally.
